Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +55

Boston Scientific Stock (BSX) Opinions on Recent Stock Decline - Quiver Quantitative

AI-generated analysis

πŸ“‰ BSX shares have tumbled more than 50% from recent peaks, trading near $48 after a guidance reduction.

πŸ’° Q1 2026 revenues reached $5.2 billion, marking an 11.58% increase compared to the prior year.

πŸ‘” CEO Michael F. Mahoney sold 160,901 shares for approximately $15 million over the last six months.

πŸ“ˆ Analysts maintain a median price target of $84.5, with targets ranging from $55 to $135.

πŸ›οΈ Representative Gilbert Ray Cisneros Jr. purchased BSX stock five times in the past six months.

πŸ“Š Institutional holdings are split, with FMR LLC reducing positions by 23.8% while Wellington Management added 94.0%.

πŸ”¬ Key growth segments WATCHMAN and ablation technologies are facing scrutiny due to slower growth.

πŸ’Ό Four firms issued buy or outperform ratings on the stock in recent months.

Bullish Signals
  • Q1 2026 revenue grew by 11.58% year-over-year to $5.2 billion, demonstrating underlying business strength despite the stock price decline.
  • Analysts maintain a median price target of $84.5, which is significantly higher than the current trading price near $48, implying substantial upside potential.
  • Insider buying activity includes purchases by David C. Habiger and Edward J. Ludwig, signaling confidence from senior management despite CEO sales.
  • Major institutional investors like Wellington Management Group (+94.0%) and Franklin Resources (+155.4%) have increased their positions in Q1 2026.
  • Wall Street consensus is bullish with four firms issuing buy or outperform ratings and no sell ratings issued recently.
Risk Factors
  • The stock has declined more than 50% from recent peaks, indicating significant short-term investor concern and volatility.
  • Guidance was reduced, which directly contributed to the sharp selloff in share price.
  • Growth is slowing in key segments including WATCHMAN and ablation technologies, raising questions about future revenue drivers.
  • Significant institutional selling occurred in Q1 2026, with FMR LLC reducing its portfolio by 23.8% and Capital World Investors by 43.6%.
Full Analysis
Boston Scientific (BSX) shares have declined over 50% from recent peaks, currently trading near $48 following a reduction in guidance. Investors are closely monitoring the impact of slower growth in key segments, specifically WATCHMAN and ablation technologies. Despite the short-term selloff, analysts maintain elevated price targets ranging between $84 and $135, suggesting the market may have overreacted to recent pressures. The company reported Q1 2026 revenues of $5.2 billion, representing an 11.58% increase year-over-year. Insider trading activity shows a mixed but generally positive signal, with Chairman Michael F. Mahoney selling shares while other executives like David C. Habiger and Edward J. Ludwig made purchases. Congressional trading also reflects bullish sentiment, with Representative Gilbert Ray Cisneros Jr. making five purchases against one sale in the past six months. Institutional investor positions are diverging significantly. While firms like FMR LLC and Capital World Investors reduced their holdings by over 20% and 43% respectively, others like Wellington Management Group and Franklin Resources increased their stakes substantially. Wall Street sentiment remains constructive, with four firms issuing buy ratings or outperform targets and a median price target of $84.5 set by 22 analysts.